
Opinion|Videos|August 30, 2024
Challenges in Risk Assessment and Biomarkers in Treatment Recommendations
The panelists examine the challenges and limitations they've faced when using the Gleason score for risk assessment in prostate cancer patients, while also highlighting how biomarker testing has informed and guided their treatment strategies.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- What are some challenges or limitations you have encountered when using the Gleason score when assessing risk in your prostate cancer patients?
- In your clinical experience, have biomarkers guided your treatment recommendations? If so which one(s)?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
2
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
3
Kari Tikkinen, MD, PhD, discusses POISE-3 findings on tranexamic acid in urologic surgery
4
Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy
5















